PT - JOURNAL ARTICLE AU - Ahn, Seungjun AU - Richards, Veronica AU - Thomas, Emmanuel AU - Jayaweera, Dushyantha AU - Govind, Varan AU - Li, Zhigang AU - Cohen, Ronald A. AU - Cook, Robert L. TI - Prevention of liver fibrosis and steatosis progression among heavy drinkers with and without HIV after 30-day drinking-reduction program AID - 10.1101/2023.02.27.23286532 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.27.23286532 4099 - http://medrxiv.org/content/early/2023/03/01/2023.02.27.23286532.short 4100 - http://medrxiv.org/content/early/2023/03/01/2023.02.27.23286532.full AB - Background This is the first attempt to assess changes in liver abnormalities before and after contingency management (CM) to reduce heavy drinking beyond 30-days of follow-up.Objective The main objective was to determine whether liver fibrosis and steatosis, measured using FibroScan, change significantly between baseline, 30-days, and 90-days among older adults who drink heavily at baseline, enrolled in the CM intervention for alcohol reduction. The secondary aim of the study was to assess whether the changes in liver outcome measures differ across alcohol consumption categories.Methods A prospective study (ClinicalTrials.gov registry: NCT03353701) of 46 older adults (63% male, 76.1% Black, mean age = 56.4) with heavy drinking at the baseline, living with or without HIV infection was evaluated. A linear mixed-effects model was used to analyze the FibroScan Transient Elastography (TE for fibrosis) and Controlled Attenuation Parameter (CAP for steatosis).Results There were no significant changes in liver fibrosis and steatosis measures after 90-days of drinking abstinence among heavy drinkers with or without stratified TE or CAP values at baseline.Conclusions CM for drinking reduction may not be effective at least short-term prospective in preventing liver fibrosis and steatosis progression for subjects without severe liver disease at baseline.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov registry: NCT03353701Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT03353701 Funding StatementThis research was supported by Award Number [NIH U01AA020797] and [NIH T32AA025877 to S.A.] from the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health and [NIH T32DA017629 to V.R.] from the National Institute on Drug Abuse of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board at University of Miami (Study Number: 20170396).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.CMcontingency management;TETransient elastography;CAPControlled attenuation parameter;HIVHuman immunodeficiency virus;PLWHPersons living with HIV;NAFLDNon-alcoholic fatty liver disease;ALTaminotransferase;GGTgamma-glutamyl transferase;ALDAlcoholic-related liver disease;FIB-4Fibrosis-4;ASTAspartate aminotransferase;TLFBAlcohol timeline followback;HCVHepatitis C